Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology
IRVINE, Calif., Aug. 25 Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Childrens Hospital Los Angeles, ranked by U.S. News & World Report as one of 'America's Best Children's Hospitals', has completed its system-wide conversion to Masimo SET pulse oximetry technology.
Masimo SET has been clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 and pulse rate measurements, even under the most difficult clinical conditions of patient motion and low peripheral perfusion--conditions common to infants and children. Its unmatched sensitivity and specificity, combined with a validated accuracy to oxygen saturations as low as 60% on patients, including cyanotic patients, helps clinicians keep their tiniest, most vulnerable patients safe. Masimo SET pulse oximetry aids the detection of congenital heart disease (CHD) and helps significantly reduce eye damage and blindness caused by retinopathy of prematurity (ROP)--one of the most common causes of visual impairment in neonatal patients.(1-5)
According to Randall Wetzel, M.D., Chair of Anesthesiology and Critical Care Medicine at Childrens Hospital Los Angeles, "Standardizing to Masimo SET allows us to more accurately assess oxygenation in children to detect life-threatening conditions earlier. It also provides a unique platform for growth with the opportunity to use Masimo Rainbow SET noninvasive measurements, such as continuous hemoglobin measurement. The ability to measure hemoglobin continuously during surgery will enable us to identify trends earlier and to more quickly and effectively manage blood and fluid administration interoperatively and in the ICUs."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are happy that Childrens Hospital Los Angeles has selected Masimo SET as their pulse oximetry technology and Pulse CO-Oximetry platform. Given what our technology has been proven to do for patients, it's always gratifying to convert a hospital to Masimo, but it is especially gratifying when it is one of the world's best children's hospitals right here in Southern California."
Childrens Hospital Los Angeles, a Level I Pediatric Trauma Center and Level III Neonatal Intensive Care Unit, treats over 93,000 children each year who need care that is so complex, it can only be provided by medical experts. With one of the largest dedicated neonatal/pediatric transport programs in the nation and the only dedicated Cardiothoracic Intensive Care Unit on the west coast, Childrens Hospital provides innovative therapies for high-risk infants transferred from other hospitals throughout Southern California and beyond.
In the past five years, approximately 900 hospitals in the U.S. have converted completely to Masimo. In addition, more than half of the top hospitals listed on the U.S. News & World Report 'Best Hospitals Honor Roll'--including four of the top five--rely on Masimo SET pulse oximetry to provide the best care to their patients.
(1) de Wahl Granelli A, et al. "Screening for Duct-Dependent Congenital Heart Disease with Pulse Oximetry: A Critical Evaluation of Strategies to Maximize Sensitivity." Acta Paediatrica 2005; 94: 1590-1596.
(2) Granelli AW, et al. "Noninvasive Peripheral Perfusion Index as a Possible Tool for Screening for Critical Left Heart Obstruction." Acta Paediatrica 2007; 96: 1455-1459.
(3) Anne de-Wahl Granelli, et al., "Impact of Pulse Oximetry Screening on the Detection of Duct Dependent Congenital Heart Disease: a Swedish Prospective Screening Study in 39,821 newborns." BMJ. 2009; 338;a3037.
(4) Armando R. Castillo, Richard Deulofeut, Augosto Sola. "Clinical Practice and SpO2 Technology in the Prevention of ROP in ELBW Infants." Publication 8440.7; 2007 Pediatric Academic Societies.
(5) Tsutum T, et al. "Clinical Evaluation of Accuracy of Masimo LNOP Blue Sensor in Cyanotic Infants." Critical Care Medicine 2006; 34(12): A56.
About Childrens Hospital Los Angeles
Founded in 1901, Childrens Hospital Los Angeles has been treating the most seriously ill and injured children in Los Angeles for more than a century, and it is acknowledged throughout the United States and around the world for its leadership in pediatric and adolescent health. Childrens Hospital is one of America's premier teaching hospitals, affiliated with the Keck School of Medicine of the University of Southern California since 1932. The Saban Research Institute of Childrens Hospital Los Angeles is among the largest and most productive pediatric research facilities in the United States. Since 1990, U.S. News & World Report and its panel of board-certified pediatricians have named Childrens Hospital Los Angeles one of the top pediatric facilities in the nation. Childrens Hospital Los Angeles is one of only 10 children's hospitals in the nation - and the only children's hospital on the West Coast - ranked in all 10 pediatric specialties in the U.S. News & World Report rankings and named to the magazine's "Honor Roll" of children's hospitals.
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET((R)), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET((R)) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO((R))), methemoglobin (SpMet((R))), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of results obtained by Childrens Hospital Los Angeles, risks related to our belief that Masimo SET will deliver sufficient sensitivity and specificity to improve patient monitoring and will achieve accuracy in oxygen saturation as low as 60% on patients, including cyanotic patients, and risks related to enabling detection of CHD and ROP, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Media Contacts: Dana Banks Masimo Corporation +1 (949) 297-7348
You May Also Like